BOSTON, May 19, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles’ offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Awards consist of (i) non-qualified stock options to purchase an aggregate of 2,169,103 shares of the Company’s common stock (“Common Stock”) with an exercise price of $7.39 per share,...

       SPF-Infused Concealer Featuring Kleair™, WHSPR™, and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin ROMEOVILLE, Ill., May 19, 2026 (GLOBE NEWSWIRE) — Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that its prototype product, Day Mode Hero Concealer SPF 50+, has won across three prototype product/chassis categories at the 2026 Cosmetics & Toiletries (C&T) Allē Awards: Anti-Aging, Color Cosmetics, and Compromised Skin. These awards mark Solésence’s fourth year of recognition at the Allē Awards since 2022. Day Mode Hero Concealer SPF 50+ leverages three proprietary Solésence technologies to deliver a daily use cosmetic that pushes the boundaries of skin care, sun care,...

Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport® (abobotulinumtoxinA) was non-inferior to Botox® (onabotulinumtoxinA) in adult patients with upper limb spasticity Patients treated with Dysport in the DIRECTION trial achieved a longer duration of response than patients treated with Botox Data will be presented at a late-breaking session at the ISPRM congress1PARIS, FRANCE – 19 MAY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today results from the only prospective, head-to-head Phase IV DIRECTION trial comparing Dysport® (abobotulinumtoxinA) to Botox® (onabotulinumtoxinA) in adults living with upper limb spasticity (ULS)1 will be presented as a late-breaking presentation at the International Society of...

MINNEAPOLIS, May 19, 2026 (GLOBE NEWSWIRE) — Alerus Financial Corporation (Nasdaq: ALRS), or the Company, closed on a sale of three non-performing loans representing a construction, land and development relationship with a total net book balance of $33.6 million as of March 31, 2026. The loans were on nonaccrual as of March 31, 2026, and represented the largest non-performing relationship in the portfolio. As of March 31, 2026, this relationship represented 62.3% of total nonperforming loans and 62.1% of total nonperforming assets. Nonperforming assets to total loans as of March 31, 2026 were 1.34%. Adjusting nonperforming assets and total loans to remove this relationship, as if the transaction had occurred on March 31, 2026, would reduce nonperforming assets to total loans to 0.51% as of such date. As of March 31, 2026, the loans...

Please see the attached notifications.  AttachmentsTilkynning – ÁSFTilkynning – EGTTilkynning – GATilkynning – KÓGTilkynning – MHTilkynning – MKITilkynning – ÓÁTilkynning – ÓÖSTilkynning – SÓÓ

ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of continuous exposure¹ SEATTLE and VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced the presentation of comprehensive long-term safety data from the ORCA-OL study at the American Thoracic Society (ATS) 2026 Annual Meeting....

During the second exercise period under the share option plan for employees of Festi hf. (hereinafter “Festi” or the “Company”) and its subsidiaries, as approved at the Company’s Annual General Meeting on 6 March 2024, the Company received notifications regarding the exercise of share options covering a total of 1,307,853 shares at an exercise price of ISK 180 per share and 213,283 shares at an exercise price of ISK 290.1 per share (exercise prices adjusted to reflect dividend payments since the granting of the options), corresponding to an aggregate amount of ISK 297,286,902. Following the exercise of these share options and in connection with the settlement of the Company’s obligations under the share option agreements, Festi has delivered a total of 1,521,136 shares to employees of the Group. Following the delivery of the aforementioned...